XGene’s Non-Opioid Pain Contender Shows Pre-/Post-Op Promise

Potential Competitor For Vertex?

 
• By Xu Hu

XGene's pain candidate has shown positive results in a US bunionectomy trial and the Chinese company is also eyeing chronic and cancer pain indications for its contender, which may provide a competitor to Vertex's suzetrigine.

Pain relief
XGene Pharmaceutical's non-opioid, dual-targeting analgesic XG005 showed positive topline Phase IIb/III results in acute pain. (Shutterstock)
Xu Hu

Read more by Xu Hu

Xu is a senior reporter and covers aspects on policy and regulations in China pharma industry within the APAC Pharma news team.

More from Interviews

More from Therapy Areas